« Sanofi Goes Hostile |
| Chemical Biology: Plastic Antibodies? »
October 4, 2010
Spamming For Site Shutdowns. Sheesh.
Well, this doesn't look encouraging. As part of its restructuring after buying Schering-Plough, Merck announced some time back that it's shedding the former Organon sites in Newhouse in Scotland and Schaijk in the Netherlands.
How's that going? Well, a correspondent forwarded me an unsolicited email he just received from "Partner International", the company hired by Merck to help divest these sites. And apparently Partner's strategy includes. . .spamming people with a one-page brochure touting this "Time Sensitive Acquisition Opportunity" for these "world class research opportunities".
My correspondent, regrettably, finds himself a bit short this month and unable to purchase either of these research sites. Perhaps someone else will idly browse their inbox and take Partner International up on this time-sensitive offer. If the message gets through the spam filter, that is.
+ TrackBacks (0) | Category: Business and Markets
POST A COMMENT
- RELATED ENTRIES
- The Worst Seminar
- Conference in Basel
- Messed-Up Clinical Studies: A First-Hand Report
- Pharma and Ebola
- Lilly Steps In for AstraZeneca's Secretase Inhibitor
- Update on Alnylam (And the Direction of Things to Come)
- There Must Have Been Multiple Chances to Catch This
- Weirdly, Tramadol Is Not a Natural Product After All